See more : Silver X Mining Corp. (AGX.V) Income Statement Analysis – Financial Results
Complete financial analysis of Precision BioSciences, Inc. (DTIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Precision BioSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Guangdong Kingshine Electronic Technology Co.,Ltd. (300903.SZ) Income Statement Analysis – Financial Results
- Banque Cantonale de Genève SA (0RMP.L) Income Statement Analysis – Financial Results
- Siam Steel Service Center Public Company Limited (SSSC.BK) Income Statement Analysis – Financial Results
- Moriya Transportation Engineering and Manufacturing Co.,Ltd. (6226.T) Income Statement Analysis – Financial Results
- First Merchants Corporation (FRMEP) Income Statement Analysis – Financial Results
Precision BioSciences, Inc. (DTIL)
About Precision BioSciences, Inc.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|
Revenue | 48.73M | 25.10M | 115.53M | 24.29M | 22.24M | 10.88M | 6.48M | 7.02M |
Cost of Revenue | 8.26M | 9.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 40.47M | 16.09M | 115.53M | 24.29M | 22.24M | 10.88M | 6.48M | 7.02M |
Gross Profit Ratio | 83.06% | 64.12% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Research & Development | 53.38M | 83.94M | 115.24M | 98.06M | 82.42M | 45.12M | 20.32M | 9.10M |
General & Administrative | 39.09M | 41.53M | 39.69M | 36.05M | 27.03M | 13.67M | 8.02M | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 39.09M | 41.53M | 39.69M | 36.05M | 27.03M | 13.67M | 8.02M | 6.10M |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -9.76M | 0.00 | 0.00 | 0.00 |
Operating Expenses | 92.46M | 125.46M | 154.93M | 134.11M | 109.44M | 58.80M | 28.34M | 15.20M |
Cost & Expenses | 92.46M | 125.46M | 154.93M | 134.11M | 109.44M | 58.80M | 28.34M | 15.84M |
Interest Income | 7.69M | 3.47M | 208.00K | 822.00K | 4.27M | 1.88M | 872.00K | 570.00K |
Interest Expense | 2.23M | 1.11M | 132.00K | 0.00 | 182.00K | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 8.26M | 9.00M | 10.20M | 9.81M | 5.32M | 2.35M | 1.44M | 640.00K |
EBITDA | -32.04M | -62.79M | -20.27M | -99.19M | -87.38M | -43.68M | -20.42M | -8.19M |
EBITDA Ratio | -65.76% | -392.35% | -24.94% | -408.45% | -392.92% | -418.62% | -313.12% | -116.72% |
Operating Income | -43.74M | -100.37M | -39.40M | -109.83M | -87.20M | -47.91M | -21.97M | -8.83M |
Operating Income Ratio | -89.76% | -399.90% | -34.11% | -452.25% | -392.14% | -440.25% | -338.90% | -125.84% |
Total Other Income/Expenses | 1.21M | 27.46M | 8.80M | 822.00K | -5.67M | 1.88M | 872.00K | 572.00K |
Income Before Tax | -42.53M | -111.64M | -30.60M | -109.01M | -92.88M | -46.04M | -21.10M | -8.26M |
Income Before Tax Ratio | -87.28% | -444.80% | -26.49% | -448.86% | -417.65% | -423.02% | -325.45% | -117.69% |
Income Tax Expense | 0.00 | 11.27M | 316.00K | 10.43M | -9.58M | 1.88M | -754.00K | -5.00K |
Net Income | -61.32M | -122.91M | -30.92M | -109.01M | -83.30M | -46.04M | -21.10M | -8.25M |
Net Income Ratio | -125.84% | -489.71% | -26.76% | -448.86% | -374.59% | -423.02% | -325.45% | -117.62% |
EPS | -15.96 | -41.95 | -15.80 | -62.85 | -59.50 | -28.17 | -18.81 | 0.00 |
EPS Diluted | -15.96 | -41.95 | -15.80 | -62.85 | -59.50 | -28.17 | -18.81 | 0.00 |
Weighted Avg Shares Out | 3.84M | 2.93M | 1.96M | 1.73M | 1.40M | 1.63M | 1.12M | 1.67B |
Weighted Avg Shares Out (Dil) | 3.84M | 2.93M | 1.96M | 1.73M | 1.40M | 1.63M | 1.12M | 1.67B |
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting
Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease
Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease
Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference
Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference
European Commission Grants Orphan Designation for iECURE’s Lead Product Candidate GTP-506 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
Source: https://incomestatements.info
Category: Stock Reports